Home Cart 0 Sign in  
X

[ CAS No. 139756-02-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 139756-02-8
Chemical Structure| 139756-02-8
Chemical Structure| 139756-02-8
Structure of 139756-02-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 139756-02-8 ]

Related Doc. of [ 139756-02-8 ]

Alternatived Products of [ 139756-02-8 ]

Product Details of [ 139756-02-8 ]

CAS No. :139756-02-8 MDL No. :MFCD02927682
Formula : C8H14N4O Boiling Point : -
Linear Structure Formula :- InChI Key :PZMXDLWWQHYXGY-UHFFFAOYSA-N
M.W : 182.22 Pubchem ID :3338044
Synonyms :

Calculated chemistry of [ 139756-02-8 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.5
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 2.0
Molar Refractivity : 50.57
TPSA : 86.93 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.06 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.17
Log Po/w (XLOGP3) : 0.5
Log Po/w (WLOGP) : 0.06
Log Po/w (MLOGP) : -0.3
Log Po/w (SILICOS-IT) : -0.13
Consensus Log Po/w : 0.26

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.37
Solubility : 7.75 mg/ml ; 0.0425 mol/l
Class : Very soluble
Log S (Ali) : -1.9
Solubility : 2.32 mg/ml ; 0.0127 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.23
Solubility : 10.9 mg/ml ; 0.0596 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.21

Safety of [ 139756-02-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 139756-02-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 139756-02-8 ]
  • Downstream synthetic route of [ 139756-02-8 ]

[ 139756-02-8 ] Synthesis Path-Upstream   1~13

  • 1
  • [ 139756-01-7 ]
  • [ 139756-02-8 ]
YieldReaction ConditionsOperation in experiment
98% With hydrogen In ethyl acetate at 50℃; Step 7
4-Amino-2-methyl-5-propyl-2H-pyrazole-3-carboxamide:
To a suspension of 2-methyl-4-nitro-5-propyl-2H-pyrazole-3-carboxamide (14.7 g, 69.3 mmol) in ethyl acetate (130 mL), was added 10percent palladium on carbon (3.3 g).
The mixture was reacted at 50° C. and 4 atm hydrogen pressure overnight.
The reaction mixture was cooled, and the catalyst was filtered off and washed with ethyl acetate and dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give the title compound (13.8 g, 98percent).
1H NMR (300 MHz, CDCl3) δ 4.12 (s, 3H), 2.84 (s, 2H), 2.55 (t, 2H, J=7.2 Hz), 1.71-1.61 (m, 2H), 0.99 (t, 3H, J=7.2 Hz); LC-MS: m/z=183 (MH)+
98.83% With palladium on activated charcoal; hydrogen In methanol at 30℃; To a solution of I-06a (10 g, 47.17 mmol) was dissolved in methanol (100 mL), then Pd/C (5 g) was added into the reaction mixture, and stirred at 30 °C under 50 Psi (345 kPa) at H2 atomsphere overnight. The reaction mixture was filtrated and the filtrate was concentrated under vacuo to give I-07a (8.5 g,98.83percent yield). ESI-MS (Mi-i): 183 calc. for C8H14N40: 182.1.
98.83% With palladium on activated charcoal; hydrogen In methanol at 30℃; Preparation of intermediate l-07a: 4-Amino-1 -methyl-3-propyl-1 /-/-pyrazole-5- carboxamide To a solution of l-06a (10 g, 47.17 mmol) was dissolved in methanol (100 ml_), then Pd/C (5 g) was added into the reaction mixture, and stirred at 30 °C under 50 Psi (345 kPa) at H2 atomsphere overnight. The reaction mixture was filtrated and the filtrate was concentrated under vacuo to give l-07a (8.5 g, 98.83percent yield). ESI-MS (M+1 ): 183 calc. for C8H14N4O: 182.1 .
93% With ammonium chloride; zinc In water at 20℃; Ionic liquid; Green chemistry 21.2 g of 4-nitro-1-methyl-3-n-propylpyrazole-5-carboxamide, 150 mL of [bmim][PF6], zinc granules13 g, 10 mL of water and 16 g of ammonium chloride were mixed. Stir at room temperature, and the reaction was followed by TLC until the starting material disappeared.Diethyl ether was added toextract (150 mL × 3), and the ether phase was combined and concentrated to dryness to give 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide (16.9 g, yield 93percent, HPLC purity It is 97.2percent.
88% With iron; ammonium chloride In ethanol; water at 80℃; for 4.5 h; Step 6: Synthesis of 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide:- 1- methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide (11.0 gin 5.1 m.ml) was dissolved in 40 ml EtOH/H20 (3:1), added Fe powder (8.7 gm 15.5 m.ml) and NH4C1 (2.75gm 5.1 m.ml). The mixture was heated up to 80 °C for 4.5 hours. The reaction mixture wascooled to 25 °C and filtered through celite and filterate was concentrated under vacuum. Trituration of the residue with either gave the 4-amino-l-methyl-3-propyl-1H-pyrazoe- 5-carboxamide as an off-white solid; Yield 88percent. ‘H NMR (400 MHz, CDC13) S 9.0l(s, 2H) 6.6(s, 2H) 4.10 (s, 3H) 2.50 (t, J=7.6Hz 3H) 1.70 (m, 2H) 1.02(t, J=7.6Hz, 3H).MASS: ESI[M+H]: 183.14

Reference: [1] Patent: US2008/194529, 2008, A1, . Location in patent: Page/Page column 57
[2] Patent: WO2014/131855, 2014, A1, . Location in patent: Page/Page column 81
[3] Patent: WO2016/20307, 2016, A1, . Location in patent: Page/Page column 51
[4] Patent: CN103044330, 2018, B, . Location in patent: Paragraph 0025; 0031-0032; 0034-0035
[5] Patent: WO2015/114647, 2015, A1, . Location in patent: Page/Page column 47; 48
[6] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 17, p. 3900 - 3907
[7] Patent: US5955611, 1999, A,
[8] Patent: US6207829, 2001, B1,
[9] Organic Process Research and Development, 2000, vol. 4, # 1, p. 17 - 22
[10] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[11] Patent: CN108117555, 2018, A, . Location in patent: Paragraph 0031; 0032; 0049
  • 2
  • [ 139755-99-0 ]
  • [ 139756-02-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1996, vol. 6, # 15, p. 1819 - 1824
[2] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 17, p. 3900 - 3907
[3] Organic Process Research and Development, 2000, vol. 4, # 1, p. 17 - 22
[4] Patent: WO2014/131855, 2014, A1,
[5] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[6] Patent: WO2015/114647, 2015, A1,
[7] Patent: WO2016/20307, 2016, A1,
  • 3
  • [ 139756-00-6 ]
  • [ 139756-02-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 17, p. 3900 - 3907
[2] Organic Process Research and Development, 2000, vol. 4, # 1, p. 17 - 22
[3] Patent: WO2014/131855, 2014, A1,
[4] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[5] Patent: WO2015/114647, 2015, A1,
[6] Patent: WO2016/20307, 2016, A1,
  • 4
  • [ 133261-07-1 ]
  • [ 139756-02-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 17, p. 3900 - 3907
[2] Patent: WO2014/131855, 2014, A1,
[3] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[4] Patent: WO2015/114647, 2015, A1,
[5] Patent: WO2016/20307, 2016, A1,
  • 5
  • [ 92945-27-2 ]
  • [ 139756-02-8 ]
Reference: [1] Patent: WO2014/131855, 2014, A1,
[2] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[3] Patent: WO2015/114647, 2015, A1,
[4] Patent: WO2016/20307, 2016, A1,
  • 6
  • [ 36983-31-0 ]
  • [ 139756-02-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2005, vol. 15, # 17, p. 3900 - 3907
[2] Patent: WO2014/131855, 2014, A1,
[3] Patent: WO2016/20307, 2016, A1,
  • 7
  • [ 107-87-9 ]
  • [ 139756-02-8 ]
Reference: [1] Patent: WO2014/131855, 2014, A1,
[2] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[3] Patent: WO2016/20307, 2016, A1,
  • 8
  • [ 360068-47-9 ]
  • [ 139756-02-8 ]
Reference: [1] Patent: WO2014/131855, 2014, A1,
[2] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 889 - 896
[3] Patent: WO2016/20307, 2016, A1,
  • 9
  • [ 304435-81-2 ]
  • [ 139756-02-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 17, p. 1983 - 1986
  • 10
  • [ 67-56-1 ]
  • [ 304435-83-4 ]
  • [ 139756-02-8 ]
  • [ 727408-28-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 17, p. 1983 - 1986
  • 11
  • [ 2100-31-4 ]
  • [ 139756-02-8 ]
  • [ 139756-04-0 ]
YieldReaction ConditionsOperation in experiment
92%
Stage #1: With thionyl chloride In dichloromethane for 3 h; Heating / reflux
Stage #2: With dmap; triethylamine In dichloromethane at 0℃; for 1 h;
Step 8
2-Methyl-4-(2-propoxybenzoylamino)-5-propyl-2H-pyrazole-3-carboxamide:
A solution of 2-propoxybenzoic acid (13.7 g, 76.1 mmol) and thionyl chloride (36.2 g, 304.4 mmol) in dry dichloromethane (80 mL) was heated for 3 hours at reflux.
The solvent and excess thionyl chloride were distilled off under reduced pressure.
The residue was taken up in dry dichloromethane (60 mL) and reacted with a solution of 4-amino-2-methyl-5-propyl-2H-pyrazole-3-carboxamide (12.6 g, 69.2 mmol), dry triethylamine (7 g, 69.2 mmol) and 4-(N,N-dimethylamino)pyridine (84.5 mg, 0.7 mmol) in dry dichloromethane (200 mL) at 0° C.
Stirring was maintained for 1 hour, and the reaction mixture was successively washed with water (150 mL), saturated aqueous sodium carbonate solution (200 mL) and saturated brine (200 mL).
The organic layer was dried over anhydrous magnesium sulfate and filtered.
The filtrate was concentrated to about 60 mL, and then hexane (150 mL) was added to give precipitate product as a white solid (22 g, 92percent).
1H NMR (300 MHz, CDCl3) δ 9.47 (s, 1H), 8.28 (d, 1H, J=7.8 Hz), 7.87 (br.s, 1H), 7.57-7.52 (m, 1H), 7.16-7.05 (m, 2H), 5.53 (s, 1H), 4.20 (t, 2H, J=6.6 Hz), 4.09 (s, 3H), 2.54 (t, 2H, J=7.5 Hz), 1.97-1.85 (m, 2H), 1.69-1.26 (m, 2H), 1.07 (t, 3H, J=7.2 Hz), 0.95 (t, 3H, J=7.5 Hz). LC-MS: m/z=345 (M+H)+
Reference: [1] Patent: US2008/194529, 2008, A1, . Location in patent: Page/Page column 57-58
[2] Patent: US2003/176696, 2003, A1,
  • 12
  • [ 54090-36-7 ]
  • [ 139756-02-8 ]
  • [ 139756-04-0 ]
Reference: [1] Patent: CN103755709, 2016, B, . Location in patent: Paragraph 0072
  • 13
  • [ 139756-02-8 ]
  • [ 139756-22-2 ]
Reference: [1] Patent: WO2014/131855, 2014, A1,
[2] Patent: WO2015/114647, 2015, A1,
[3] Patent: WO2016/20307, 2016, A1,
[4] Chemical Communications, 2016, vol. 52, # 67, p. 10245 - 10248
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 139756-02-8 ]

Udenafil Intermediates

Chemical Structure| 51387-90-7

[ 51387-90-7 ]

2-(2-Aminoethyl)-1-methylpyrrolidine

Related Functional Groups of
[ 139756-02-8 ]

Amides

Chemical Structure| 247584-10-7

[ 247584-10-7 ]

4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide hydrochloride

Similarity: 0.99

Chemical Structure| 136678-93-8

[ 136678-93-8 ]

1,3-Dimethyl-1H-pyrazole-5-carboxamide

Similarity: 0.84

Chemical Structure| 1397683-79-2

[ 1397683-79-2 ]

1H-Pyrazole-3,5-dicarboxamide

Similarity: 0.68

Chemical Structure| 1029721-02-5

[ 1029721-02-5 ]

4-Oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylic acid

Similarity: 0.67

Chemical Structure| 1643141-19-8

[ 1643141-19-8 ]

tert-Butyl ((5-carbamoyl-1-methyl-1H-pyrazol-3-yl)methyl)(methyl)carbamate

Similarity: 0.66

Amines

Chemical Structure| 247584-10-7

[ 247584-10-7 ]

4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide hydrochloride

Similarity: 0.99

Chemical Structure| 136678-93-8

[ 136678-93-8 ]

1,3-Dimethyl-1H-pyrazole-5-carboxamide

Similarity: 0.84

Chemical Structure| 28466-21-9

[ 28466-21-9 ]

1,3,5-Trimethyl-1H-pyrazol-4-amine

Similarity: 0.72

Chemical Structure| 1185303-62-1

[ 1185303-62-1 ]

4-Amino-1,3,5-trimethylpyrazole hydrochloride

Similarity: 0.71

Chemical Structure| 852227-87-3

[ 852227-87-3 ]

1-(1,3-Dimethyl-1H-pyrazol-5-yl)-N-methylmethanamine

Similarity: 0.68

Related Parent Nucleus of
[ 139756-02-8 ]

Pyrazoles

Chemical Structure| 247584-10-7

[ 247584-10-7 ]

4-Amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide hydrochloride

Similarity: 0.99

Chemical Structure| 136678-93-8

[ 136678-93-8 ]

1,3-Dimethyl-1H-pyrazole-5-carboxamide

Similarity: 0.84

Chemical Structure| 864068-96-2

[ 864068-96-2 ]

1-Methyl-3-phenyl-1H-pyrazole-5-carbaldehyde

Similarity: 0.73

Chemical Structure| 25016-09-5

[ 25016-09-5 ]

1,3-Dimethyl-1H-pyrazole-5-carbaldehyde

Similarity: 0.72

Chemical Structure| 28466-21-9

[ 28466-21-9 ]

1,3,5-Trimethyl-1H-pyrazol-4-amine

Similarity: 0.72